Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Etern Therapeutics (Wuxi) Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner within 1 distinct art unit, reflecting a point of contact for the company's current patent prosecution. This concentration suggests that the company is currently prioritizing a specific therapeutic or pharmaceutical innovation rather than a wide-ranging portfolio of diverse applications.
The busiest examiner, BELL, SARA ELIZABETH, is responsible for 1 busiest examiner pending action. Since there is only 1 pending office action in total, this examiner manages the entire active portfolio. Practitioners should note that the prosecution is currently limited to this specific examiner and art unit combination. Success for the company's current filing depends on navigating the specific examination style of this individual within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264765 | METHODS OF MODULATING ANDROGEN RECEPTOR CONDENSATES | BELL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264765 | METHODS OF MODULATING ANDROGEN RECEPTOR CONDENSATES | BELL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264765 | METHODS OF MODULATING ANDROGEN RECEPTOR CONDENSATES | BELL, SARA ELIZABETH | 1625 | §102§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEtern Therapeutics (Wuxi) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sara Elizabeth Bell has the most, with 1 of Etern Therapeutics (Wuxi) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
